Phase II Trial of Saracatinib (AZD0530), an Oral SRC-inhibitor for the Treatment of Patients with Hormone Receptor-negative Metastatic Breast Cancer

References

Page 1

	Year	Citations
Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer Massimo Cristofanilli, G. Thomas Budd, Matthew J. Ellis, New England Journal of Medicine	2004	4.5K
Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias Moshe Talpaz, Neil P. Shah, Hagop M. Kantarjian, New England Journal of Medicine	2006	1.8K
Latent Bone Metastasis in Breast Cancer Tied to Src-Dependent Survival Signals Xiang H.-F. Zhang, Qiongqing Wang, William L. Gerald, Cancer Cell Breast OncologyEndocrine-related CancerMedicinePathologyBreast Cancer	2009	653
Intermittent Target Inhibition With Dasatinib 100 mg Once Daily Preserves Efficacy and Improves Tolerability in Imatinib-Resistant and -Intolerant Chronic-Phase Chronic Myeloid Leukemia Neil P. Shah, Hagop M. Kantarjian, Dong‐Wook Kim, Journal of Clinical Oncology	2008	487
Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/“triple-negative” breast cancer cell lines growing in vitro Richard S. Finn, Judy Dering, Charles Ginther, Breast Cancer Research and Treatment Breast OncologyPathologyCancer BiologyBreast Cancer SubtypeTumor Biology	2007	400
Pleural Effusion in Patients With Chronic Myelogenous Leukemia Treated With Dasatinib After Imatinib Failure Alfonso Quintás‐Cardama, Hagop M. Kantarjian, Susan O’Brien, Journal of Clinical Oncology	2007	388
Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial Hagop Kantarjian, Ricardo Pasqüini, Nelson Hamerschlak, Blood	2007	377
p27 Phosphorylation by Src Regulates Inhibition of Cyclin E-Cdk2 Isabel Chu, Jun Sun, Angel Arnaout, Cell Signal TransductionCell RegulationMolecular PathwayReceptor Tyrosine KinaseP27 Phosphorylation	2007	368
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib Andreas Hochhaus, Michele Baccarani, Michael W. Deininger, Leukemia Chronic PhaseHematological MalignancyImmunologyHematologyMyeloid Neoplasia	2008	352
Identification of Candidate Molecular Markers Predicting Sensitivity in Solid Tumors to Dasatinib: Rationale for Patient Selection Fei Huang, Karen A. Reeves, Xia Han, Cancer Research	2007	337

Page 1